Clinical Trial Update: Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ACER-001 (sodium phenylbutyrate) for Medium-chain Acyl-CoA Dehydrogenase Deficiency has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medium-chain Acyl-coa Dehydrogenase Deficiency

Drugs mentioned

• ACER-001 (sodium phenylbutyrate)

Snippet

Sponsor: Jerry Vockley, MD, PhD | Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency | Phase 2 | Status: SUSPENDED